These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
395 related articles for article (PubMed ID: 26749586)
1. Treatment of recurrent and platinum-refractory stage IV non-small cell lung cancer with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as a single agent. Saxena A; Schneider BJ; Christos PJ; Audibert LF; Cagney JM; Scheff RJ Med Oncol; 2016 Feb; 33(2):13. PubMed ID: 26749586 [TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer. Socinski MA; Okamoto I; Hon JK; Hirsh V; Dakhil SR; Page RD; Orsini J; Yamamoto N; Zhang H; Renschler MF Ann Oncol; 2013 Sep; 24(9):2390-6. PubMed ID: 23842283 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Nab-Paclitaxel as Second-line Chemotherapy for Locally Advanced and Metastatic Non-small Cell Lung Cancer. Gong W; Sun P; Mu Z; Liu J; Yu C; Liu A Anticancer Res; 2017 Aug; 37(8):4687-4691. PubMed ID: 28739772 [TBL] [Abstract][Full Text] [Related]
4. Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer. Rizvi NA; Riely GJ; Azzoli CG; Miller VA; Ng KK; Fiore J; Chia G; Brower M; Heelan R; Hawkins MJ; Kris MG J Clin Oncol; 2008 Feb; 26(4):639-43. PubMed ID: 18235124 [TBL] [Abstract][Full Text] [Related]
5. Survival, quality-adjusted survival, and other clinical end points in older advanced non-small-cell lung cancer patients treated with albumin-bound paclitaxel. Langer CJ; Hirsh V; Okamoto I; Lin FJ; Wan Y; Whiting S; Ong TJ; Renschler MF; Botteman MF Br J Cancer; 2015 Jun; 113(1):20-9. PubMed ID: 26035702 [TBL] [Abstract][Full Text] [Related]
6. Phase II Study of the Modified Weekly Nab-paclitaxel Regimen in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer. Yoshimura N; Sawa K; Nakai T; Matsumoto Y; Mitsuoka S; Kimura T; Asai K; Yana T; Kawaguchi T; Hirata K Am J Clin Oncol; 2021 Dec; 44(12):613-618. PubMed ID: 34753884 [TBL] [Abstract][Full Text] [Related]
7. Nab-paclitaxel in older patients with non-small cell lung cancer who have developed disease progression after platinum-based doublet chemotherapy. Weiss JM; Pennell N; Deal AM; Morgensztern D; Bradford DS; Crane J; West HJ; Lee C; Pecot C; Stevenson JP; Irvin W; Socinski M; Stinchcombe T; Villaruz LC; Muss HB Cancer; 2020 Mar; 126(5):1060-1067. PubMed ID: 31943168 [TBL] [Abstract][Full Text] [Related]
8. Stromal Caveolin-1 Is Associated With Response and Survival in a Phase II Trial of nab-Paclitaxel With Carboplatin for Advanced NSCLC Patients. Bertino EM; Williams TM; Nana-Sinkam SP; Shilo K; Chatterjee M; Mo X; Rahmani M; Phillips GS; Villalona-Calero MA; Otterson GA Clin Lung Cancer; 2015 Nov; 16(6):466-74. PubMed ID: 26123189 [TBL] [Abstract][Full Text] [Related]
9. Phase II trial of nanoparticle albumin-bound paclitaxel, carboplatin, and bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancer. Reynolds C; Barrera D; Jotte R; Spira AI; Weissman C; Boehm KA; Pritchard S; Asmar L J Thorac Oncol; 2009 Dec; 4(12):1537-43. PubMed ID: 19887966 [TBL] [Abstract][Full Text] [Related]
10. Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial. Shitara K; Takashima A; Fujitani K; Koeda K; Hara H; Nakayama N; Hironaka S; Nishikawa K; Makari Y; Amagai K; Ueda S; Yoshida K; Shimodaira H; Nishina T; Tsuda M; Kurokawa Y; Tamura T; Sasaki Y; Morita S; Koizumi W Lancet Gastroenterol Hepatol; 2017 Apr; 2(4):277-287. PubMed ID: 28404157 [TBL] [Abstract][Full Text] [Related]
11. A retrospective analysis of safety and efficacy of weekly nab-paclitaxel as second-line chemotherapy in elderly patients with advanced squamous non-small-cell lung carcinoma. Jin F; Zhu H; Shi F; Kong L; Yu J Clin Interv Aging; 2016; 11():167-73. PubMed ID: 26929611 [TBL] [Abstract][Full Text] [Related]
12. ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin-bound paclitaxel with or without CC-486 as second-line treatment for advanced nonsquamous non-small cell lung cancer (NSCLC). Morgensztern D; Cobo M; Ponce Aix S; Postmus PE; Lewanski CR; Bennouna J; Fischer JR; Juan-Vidal O; Stewart DJ; Fasola G; Ardizzoni A; Bhore R; Wolfsteiner M; Talbot DC; Jin Ong T; Govindan R; On Behalf Of The Abound L Investigators Cancer; 2018 Dec; 124(24):4667-4675. PubMed ID: 30383906 [TBL] [Abstract][Full Text] [Related]
13. Retrospective analysis of the effectiveness and tolerability of nab-paclitaxel in Chinese elderly patients with advanced non-small-cell lung carcinoma. Wang S; Liang Q; Chi Y; Zhuo M; An T; Duan J; Wang Z; Wang Y; Zhong J; Yang X; Chen H; Wang J; Zhao J Thorac Cancer; 2020 May; 11(5):1149-1159. PubMed ID: 32162417 [TBL] [Abstract][Full Text] [Related]
14. A phase II open-label clinical study of comparing nab-paclitaxel with pemetrexed as second-line chemotherapy for patients with stage IIIB/IV non-small-cell lung cancer. Liu Z; Wei Z; Hu Y; Gao F; Hao L; Fang P; Sun S; Li J; Jiao S Med Oncol; 2015 Aug; 32(8):216. PubMed ID: 26168982 [TBL] [Abstract][Full Text] [Related]
15. Prospective study on nanoparticle albumin-bound paclitaxel in advanced breast cancer: clinical results and biological observations in taxane-pretreated patients. Fabi A; Giannarelli D; Malaguti P; Ferretti G; Vari S; Papaldo P; Nisticò C; Caterino M; De Vita R; Mottolese M; Iacorossi L; Cognetti F Drug Des Devel Ther; 2015; 9():6177-83. PubMed ID: 26640370 [TBL] [Abstract][Full Text] [Related]
16. Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life. Palumbo R; Sottotetti F; Trifirò G; Piazza E; Ferzi A; Gambaro A; Spinapolice EG; Pozzi E; Tagliaferri B; Teragni C; Bernardo A Drug Des Devel Ther; 2015; 9():2189-99. PubMed ID: 25931813 [TBL] [Abstract][Full Text] [Related]
17. Phase II evaluation of nanoparticle albumin-bound paclitaxel in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer. Teneriello MG; Tseng PC; Crozier M; Encarnacion C; Hancock K; Messing MJ; Boehm KA; Williams A; Asmar L J Clin Oncol; 2009 Mar; 27(9):1426-31. PubMed ID: 19224848 [TBL] [Abstract][Full Text] [Related]
18. nab-paclitaxel for the management of patients with advanced non-small-cell lung cancer. Hirsh V Expert Rev Anticancer Ther; 2014 Feb; 14(2):129-41. PubMed ID: 24467217 [TBL] [Abstract][Full Text] [Related]
19. A phase II study of nab-paclitaxel plus carboplatin in combination with thoracic radiation in patients with locally advanced non-small-cell lung cancer. Hasegawa T; Futamura Y; Horiba A; Yoshida T; Suzuki T; Kato T; Kaito D; Ohno Y; Iida T; Hayashi S; Sawa T J Radiat Res; 2016 Jan; 57(1):50-4. PubMed ID: 26442970 [TBL] [Abstract][Full Text] [Related]
20. Phase II trial of weekly nab-paclitaxel for previously treated advanced non-small cell lung cancer: Kumamoto thoracic oncology study group (KTOSG) trial 1301. Sakata S; Saeki S; Okamoto I; Otsubo K; Komiya K; Morinaga R; Yoneshima Y; Koga Y; Enokizu A; Kishi H; Hirosako S; Yamaguchi E; Aragane N; Fujii S; Harada T; Iwama E; Semba H; Nakanishi Y; Kohrogi H Lung Cancer; 2016 Sep; 99():41-5. PubMed ID: 27565912 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]